ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), developers of novel treatments to reduce cholesterol in the bloodstream, announced the United States commercial availability of Nexlizet tablets.
Nexlizet is a combination of bempedoic acid and ezetimibe. Bempedoic acid is the Esperion-developed active ingredient in Nexletol tablets, approved by the U.S. Food and Drug Administration and introduced earlier this year. It is intended for use, along with diet and the maximally tolerated dose of already existing statin anti-cholesterol drugs, for patients with high cholesterol and cardiovascular disease who require additional lowering of LDL-C, the so-called bad cholesterol.
Nexlizet reduced by a mean of 38 percent compared to placebo when added on to maximally tolerated statins, according to study results published in the European Journal of Preventive Cardiology.
“More than ever, health care providers are seeking more options to help the millions of patients reach their cholesterol goals and address their long-term health needs,” said Mark Glickman, chief commercial officer of Esperion. “Nexlizet is highly anticipated, so we are responding by accelerating its commercial availability.”
Esperion is committed to providing oral, once-daily non-statin LDL-C lowering treatment options that are affordable and accessible. Eligible patients with commercial drug insurance coverage may pay as little as $10 per fill, up to a 3-month supply. For those that need Nexlizet or Nexletol, Esperion’s mission is to considerably reduce cost as a burden for patients as they strive to achieve their long-term LDL-C goals.
Health care providers with questions regarding Nexlizet may call (833) 377-7633 and select Option 1, Monday through Friday from 8 a.m. to 8 p.m. Questions may also be submitted via email at medinfo@esperion.com.
More about Esperion at www.esperion.com.
Nexlizet reduces elevated LDL-C by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Side effects have included elevation in uric acid and tendon rupture. For full prescribing information, visit https://pi.esperion.com/nexlizet/nexlizet-pi.pdf.